IVA Inventiva SA: Market Capitalization to Book Value Ratio

Official company branding of Inventiva Pharma (IVA)

The price action history of Inventiva S.A. (IVA) demonstrates a current metric of 12.64. The French biotech firm is developing methods to combat liver pathologies, leveraging alliances with global industry behemoths to create anti-fibrosis treatments. The team unites scientists through a stock option system and an academic approach to work. Business growth depends on R&D progress and stringent FDA regulatory requirements in the NASH segment.

Inventiva S.A. (IVA) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026
Finished products of Inventiva SA

Developing robotic systems for small molecule screening in the treatment of liver fibrosis requires significant capital expenditures, making asset value analysis critically important. By examining the market valuation of book capitalization, an investor compares the current share price with net assets to determine whether the market price of Inventiva S.A. (IVA) is justified by tangible assets or is subject to excessive speculative risks.